The CD70-targeting CTX131 heads for the scrapheap.
ApexOnco Front Page
Recent articles
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
Supply continues to cause headaches for radiopharmaceutical developers.
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
The group is keeping faith with the novel target KLK2.
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.